title: [Treatment of malignant non-Hodgkin's lymphoma. Economic impact of rituximab (Mabthera) versus conventional chemotherapy].
abstract: The monoclonal antibody rituximab, targeted against the CD20 antigen, has shown efficacy in patients with follicular lymphoma who relapse or fail to response to conventional chemotherapy. We evaluated the economic impact of using rituximab for the treatment of non-Hodgkin's lymphoma (NLH) in comparison with conventional chemotherapy protocols (CHOP or CHVP). In this retrospective study conducted between 1998 and 2000, the direct costs of treating inpatients with NHL rituximab (n=20) or CHOP/CHVP (n=17) were compared. Results, including costs of administering chemotherapy and adverse events, showed that the average cost per patient was comparable for the two strategies (9700 euro for rituximab, versus 8487 euro for conventional chemotherapy). In the rituximab group, the cost was mostly due to drug purchases. In the conventional chemotherapy group, outlays were related to drug-induced toxicity and longer hospital stay. Our results were similar to others described in the literature. Prospective studies are nevertheless needed for confirmation. For first-line treatement, the difference in the cost-effectiveness-ratio between rituximab and conventional drugs might be smaller, but sound data are not yet available.
authors.affiliation: Service de Pharmacie et Toxicologie, Groupe Hospitalier Pitié-Salpêtrière, Paris.
authors.forename: Miriam
authors.initials: M
authors.lastname: Malliti
authors.forename: Helga
authors.initials: H
authors.lastname: Junot
authors.forename: Marie-Hélène
authors.initials: MH
authors.lastname: Fievet
authors.forename: Jean
authors.initials: J
authors.lastname: Gabarre
authors.forename: Namik
authors.initials: N
authors.lastname: Taright
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Vernant
authors.forename: Alain
authors.initials: A
authors.lastname: Thuillier
mesh_terms: D000740:Anemia / Q000139:chemically induced; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics / Q000627:therapeutic use*; D003365:Costs and Cost Analysis; D003520:Cyclophosphamide / Q000191:economics / Q000627:therapeutic use*; D004317:Doxorubicin / Q000191:economics / Q000627:therapeutic use*; D004342:Drug Hypersensitivity / Q000209:etiology; D005260:Female; D006760:Hospitalization / Q000191:economics / Q000706:statistics & numerical data; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000191:economics; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D011241:Prednisone / Q000191:economics / Q000627:therapeutic use*; D012189:Retrospective Studies; D000069283:Rituximab; D013713:Teniposide / Q000191:economics / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced; D014750:Vincristine / Q000191:economics / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D013713:Teniposide; D011241:Prednisone